Insider Selling: Heartflow (NASDAQ:HTFL) CEO Sells 12,837 Shares of Stock

Heartflow, Inc. (NASDAQ:HTFL) CEO John C.M. Farquhar sold 12,837 shares of Heartflow stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $22.66, for a total value of $290,886.42. Following the sale, the chief executive officer owned 581,450 shares in the company, valued at $13,175,657. This trade represents a 2.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

John C.M. Farquhar also recently made the following trade(s):

• On Tuesday, February 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $27.46, for a total value of $619,552.52.

Heartflow Trading Down 6.4%

NASDAQ:HTFL traded down $1.42 during mid-day trading on Thursday, reaching $20.79. 1,420,147 shares of the stock were exchanged, compared to its average volume of 1,325,991. Heartflow, Inc. has a 1 year low of $20.13 and a 1 year high of $41.22. The company has a 50 day simple moving average of $27.83 and a 200-day simple moving average of $30.76.

Hedge Funds Weigh In On Heartflow

Several institutional investors and hedge funds have recently added to or reduced their stakes in HTFL. Caitong International Asset Management Co. Ltd purchased a new position in shares of Heartflow during the 4th quarter worth approximately $27,000. TFC Financial Management Inc. purchased a new stake in shares of Heartflow in the third quarter valued at approximately $40,000. Russell Investments Group Ltd. acquired a new position in Heartflow during the fourth quarter worth $45,000. Legal & General Group Plc acquired a new position in Heartflow during the third quarter worth $59,000. Finally, Strs Ohio purchased a new position in Heartflow in the fourth quarter worth $99,000.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $40.00 target price on shares of Heartflow in a report on Monday. Stifel Nicolaus raised their price objective on shares of Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Weiss Ratings restated a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th. Wells Fargo & Company started coverage on Heartflow in a report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 price target for the company. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Heartflow has an average rating of “Moderate Buy” and an average price target of $38.50.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.